학술논문
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS1114-TPS1114, 1p
Subject
Language
ISSN
0732183X